D-Wave Quantum Inc.

🇺🇸New York Stock Exchange
Back to all articles
D-Wave Quantum Inc. stock analysis QBTS overview
Somewhat Bullish +50

Zapata Quantum to Present Alongside Fortune 500 and Quantum Leaders at Upcoming Investor and Industry Conferences

🗓️ Zapata Quantum executives Sumit Kapur and Dr. Jonathan Olson will present at multiple investor and industry conferences between May 27 and June 26, 2026.

🏙️ A fireside chat led by CEO Sumit Kapur on software and applications in quantum computing is scheduled for the Benchmark/StoneX Quantum Computing Summit in Washington DC on June 17.

🔬 Dr. Olson will participate in a panel at The Economist’s Commercialising Quantum conference in London on June 16 alongside leaders from Rolls-Royce and Airbus discussing commercial quantum advantage.

💊 On June 26, CEO Sumit Kapur will deliver a keynote on Zapata’s Nature Biotechnology paper regarding quantum-enabled drug discovery, which was recognized as one of the journal's Top 10 Papers of 2025.

🤖 Dr. Olson will join a panel at The Economist conference on June 26 focusing on the convergence of quantum computing, AI, and high-performance computing with enterprise leaders from Verizon, Nestlé, and the FCA.

🎯 Zapata executives will host a roundtable discussion on pharmaceutical quantum capabilities on June 25 at The Economist’s Commercialising Quantum event in London.

💻 Attendees can meet with Zapata team members and demo its Quantum Application Intelligence platform at Booth E4 at various conference locations including the Westin Georgetown.

🎓 Zapata is scheduled to participate in an invite-only session at a16z Tech Week Boston on May 27 regarding quantum systems, AI, and sovereign capital at the Hult Center.

🧠 The Company positions itself as a hardware-agnostic, pure-play quantum software firm with over 60 granted or pending patents developed over seven years.

🏛️ Zapata is the only organization to have participated across all technical areas of DARPA’s Quantum Benchmarking program and works with Fortune 500 enterprises.

💊 The company's study on quantum-enabled drug discovery was featured on the cover of Nature Biotechnology's December 2025 issue in collaboration with Dana-Farber Cancer Institute, the University of Toronto, and Insilico Medicine.

🌐 Zapata supports applications across cryptography, pharmaceuticals, finance, materials discovery, defense, and other sectors through its software platform.

🏢 Institutional investors interested in meetings with Zapata executives at the Washington DC conference should contact their Benchmark/StoneX representative or email Richard Land of Alliance Advisors Investor Relations.

Bullish Signals
  • CEO Sumit Kapur and Co-founder Dr. Jonathan Olson will present alongside Fortune 500 leaders and industry pioneers at major upcoming conferences, highlighting Zapata's strong market positioning.
  • Zapata Quantum was recognized as one of Nature Biotechnology's Top 10 Papers of 2025 for its pioneering work in quantum-enabled drug discovery with Dana-Farber Cancer Institute.
  • The company maintains a robust intellectual property portfolio with more than 60 granted and pending patents developed over seven years across key sectors like cryptography, finance, and pharmaceuticals.
  • Zapata has successfully completed an oversubscribed $15 million strategic financing, demonstrating strong investor confidence in its restructuring and growth trajectory.
  • The company is the only organization to have participated across all technical areas of DARPA's Quantum Benchmarking program, validating its comprehensive technical capabilities.
  • Industry leaders such as Rolls-Royce, Airbus, Verizon, Nestlé, and the UK Financial Conduct Authority are engaging with Zapata's platform at upcoming events.
  • Zapata holds a foundational patent for interoperable quantum software across key global markets, reinforcing its position as a hardware-agnostic pure-play leader.
Risk Factors
  • The article describes upcoming investor conferences but lacks any substantive financial performance data, recent earnings guidance, or specific revenue figures to validate the company's growth claims beyond press releases.
  • Zapata Quantum trades on the OTC market (OTC: ZPTA), which often signals lower liquidity and potentially higher volatility compared to major exchange-listed competitors in the quantum computing space.
  • The article mentions a '$15 Million Strategic Financing' completed 21 days ago, but does not detail the dilution impact on existing shareholders or provide details on the specific terms that could lead to future financial strain if follow-on funding is required.
  • While the company highlights partnerships with major entities like Rolls-Royce and Airbus at conferences, the text provides no concrete revenue generated from these collaborations or evidence of commercialized products to date, leaving open the risk that these are still pilot-phase endeavors without immediate profit contribution.
Full Analysis
Zapata Quantum (OTC: ZPTA), a pioneer in quantum computing application and algorithm development, announced that its senior executives, including CEO Sumit Kapur and Co-founder Dr. Jonathan Olson, will present at several upcoming investor and industry conferences spanning from late May through late June 2026. The company intends to showcase its hardware-agnostic software platform and discuss the commercialization of quantum computing across various sectors including pharmaceuticals, finance, and materials discovery. At the Benchmark/StoneX Quantum Computing Summit in Washington DC on June 17, 2026, Kapur will lead a fireside chat regarding the role of software in the next phase of quantum computing and will host one-on-one meetings with institutional investors at the Westin Georgetown. Dr. Olson is scheduled to speak on a panel at The Economist’s Commercialising Quantum event in London on June 16 alongside leaders from Rolls-Royce and Airbus, focusing on the path to commercial quantum advantage. The company also plans to highlight its research achievements at Quantuum, AI, and the Reallocation of Capital during a16z Tech Week Boston on May 27 and present a keynote on drug discovery at The Economist’s event on June 26. This presentation will focus on a study recognized as one of Nature Biotechnology's Top 10 Papers of 2025, which was developed in collaboration with Dana-Farber Cancer Institute, the University of Toronto, and Insilico Medicine and featured on the journal's December 2025 cover. During these appearances, Zapata aims to demonstrate its Quantum Application Intelligence platform and engage with investors about its strategic roadmap. The company holds a portfolio of more than 60 granted and pending patents and is the only organization to have participated across all technical areas of DARPA's Quantum Benchmarking program. Executives will also host roundtables on pharmaceutical development strategies for quantum capabilities at the London event.